Study summary · research use only
Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mouse study used female transgenic FVB mice carrying the HER-2/neu breast cancer gene, given monthly subcutaneous injections of Vilon or Epithalon (1 microgram for 5 consecutive days) starting at 2 months of age. Epithalon treatment was associated with reduced tumor development: maximum breast adenocarcinoma size was 33% lower than controls. HER-2/neu mRNA in breast tumors of Epithalon-treated mice was 3.7 times lower than in control animals. The authors suggest this association with reduced tumor development may relate to suppressed HER-2/neu expression.
Abstract
Female transgenic FVB mice carrying breast cancer gene HER-2/neu were monthly injected with Vilon or Epithalon (1 microgram subcutaneously for 5 consecutive days) starting from the 2nd month of life. Epithalon markedly inhibited neoplasm development: the maximum size of breast adenocarcinomas was 33% lower than in the control (p < 0.05). The intensity of HER-2/neu mRNA expression in breast tumors of Epithalon-treated mice was 3.7 times lower than in control animals. These results indicate that Epithalon inhibits breast tumor development in transgenic mice, which is probably related to suppression of HER-2/neu expression.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.